Condition
Relapsed Lymphoma
Total Trials
4
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (2)
Trial Status
Completed3
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06563596Phase 2Recruiting
Epco, Zanu, Ritux for R/R FL or MZL
NCT01742988Phase 1Completed
Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
NCT01929720Not ApplicableCompleted
Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors
NCT00054808Phase 2Completed
Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma
Showing all 4 trials